Moleculin Biotech, Inc. — Director's Dealing 2025

Jun 19, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2025-06-16

Reporting Person: KLEMP WALTER V (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-16	Common Stock	M	1667	—	Acquired	58702	Direct
2025-06-16	Common Stock	F	406	$0.6852	Disposed	58296	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-16	Restricted Stock Units	$	M	1667	Disposed		Common Stock (1667)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Shares withheld for payment of taxes upon vesting of restricted stock unit awards

F3: On June 16, 2021, the reporting person was granted 6,668 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.